MedTrace Logo

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma

NCT01632826 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2019-11-12

No results posted yet for this study

Summary

To provide pomalidomide access to relapsed/refractory multiple myeloma subjects with a likelihood of benefit from the pomalidomide treatment while the medication is not commercially available

Conditions

Interventions

DRUG

Pomalidomide

4 mg daily for 21 days in a 28 day cycle until disease progression or other reasons for treatment discontinuation

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Lars Sternas, MD, PhD · Celgene Corporation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01632826 on ClinicalTrials.gov